Compare KTOS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTOS | HALO |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.1B |
| IPO Year | 1999 | 2001 |
| Metric | KTOS | HALO |
|---|---|---|
| Price | $47.97 | $71.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 11 |
| Target Price | ★ $96.71 | $78.64 |
| AVG Volume (30 Days) | ★ 4.3M | 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | 0.07 | ★ 1.22 |
| Revenue | ★ $751,900,000.00 | $151,862,000.00 |
| Revenue This Year | $26.15 | $28.24 |
| Revenue Next Year | $23.43 | $12.56 |
| P/E Ratio | $735.57 | ★ $57.07 |
| Revenue Growth | ★ 12.44 | N/A |
| 52 Week Low | $39.00 | $51.06 |
| 52 Week High | $134.00 | $82.22 |
| Indicator | KTOS | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 57.48 |
| Support Level | N/A | $67.94 |
| Resistance Level | $78.77 | $71.38 |
| Average True Range (ATR) | 3.65 | 2.03 |
| MACD | -0.78 | -0.11 |
| Stochastic Oscillator | 0.84 | 79.32 |
Kratos Defense & Security Solutions Inc develops and fields transformative, affordable technology, platforms, and systems. The company has two segments; The Kratos Government Solutions (KGS) segment is comprised of an aggregation of KGS operating segments, including its microwave electronic products, space, training, and cybersecurity, C5ISR/modular systems, turbine technologies, and defense and rocket support services operating segments and The Unmanned Systems segment consists of unmanned aerial, unmanned ground, unmanned seaborne and related command, control, and communications system businesses. The company derives a majority of its revenue from the Kratos Government Solutions segment.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.